Moherndran Archary1,2, Helen Mcllleron3, Raziya Bobat2, Philip LaRussa4, Thobekile Sibaya2, Lubbe Wiesner3, Stefanie Hennig5. 1. Department of Paediatrics and Children Health, King Edward VIII Hospital, University of KwaZulu-Natal, Durban, South Africa. 2. Department of Paediatrics and Children Health, University of KwaZulu-Natal, Durban, South Africa. 3. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. 4. Department of Paediatrics, College of Physicians & Surgeons, Columbia University, New York, New York, USA. 5. School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia.
Abstract
AIMS: Describe the pharmacokinetics (PK) of the antiretroviral drugs abacavir and lamivudine in malnourished paediatric patients and relate to viral load outcomes after 12 and 48 weeks of treatment. METHODS:Severely malnourished human immunodeficiency virus-infected children were randomized to early (within 14 days) or delayed (after nutritional recovery) initiation of antiretroviral treatment (ART) using World Health Organization weight-band dosages. Abacavir and lamivudine concentrations were measured as a secondary objective on day 1 and day 14 and patients were followed-up to week 48. Population PK of abacavir and lamivudine were described using NONMEM. RESULTS: In total, 623 abacavir and 627 lamivudine concentrations were collected from 75 paediatric patients aged 0.1-10.8 (median 1.4) years. Abacavir PK was described by a 2-compartment model, patients randomized to early ART showed increased bioavailability of 31%. Apparent clearance (CL/F, L/h/7 kg) of abacavir increased from day 1 to day 14 from 3.33 (95% confidence interval 2.71-4.12) to 5.86 (95% confidence interval 4.78-7.3). A 1-compartment model described lamivudine PK, variability on CL/F was explained by maturation with age, with age at half-matured CL/F being 4 months. For both drugs allometrically scaled total body weight was related to CL/F and apparent volume of distribution. PK exposure did not correlate with virological outcomes or death at 12 or 48 weeks. CONCLUSION: Increases in Abacavir's CL/F between day 1 to day 14, bioavailability and PK variability with early start of ART was found in this cohort of severely malnourished children; however, these changes did not influence virological outcomes. The study supports the use of weight-band dosage tables.
RCT Entities:
AIMS: Describe the pharmacokinetics (PK) of the antiretroviral drugs abacavir and lamivudine in malnourished paediatric patients and relate to viral load outcomes after 12 and 48 weeks of treatment. METHODS: Severely malnourished human immunodeficiency virus-infectedchildren were randomized to early (within 14 days) or delayed (after nutritional recovery) initiation of antiretroviral treatment (ART) using World Health Organization weight-band dosages. Abacavir and lamivudine concentrations were measured as a secondary objective on day 1 and day 14 and patients were followed-up to week 48. Population PK of abacavir and lamivudine were described using NONMEM. RESULTS: In total, 623 abacavir and 627 lamivudine concentrations were collected from 75 paediatric patients aged 0.1-10.8 (median 1.4) years. Abacavir PK was described by a 2-compartment model, patients randomized to early ART showed increased bioavailability of 31%. Apparent clearance (CL/F, L/h/7 kg) of abacavir increased from day 1 to day 14 from 3.33 (95% confidence interval 2.71-4.12) to 5.86 (95% confidence interval 4.78-7.3). A 1-compartment model described lamivudine PK, variability on CL/F was explained by maturation with age, with age at half-matured CL/F being 4 months. For both drugs allometrically scaled total body weight was related to CL/F and apparent volume of distribution. PK exposure did not correlate with virological outcomes or death at 12 or 48 weeks. CONCLUSION: Increases in Abacavir's CL/F between day 1 to day 14, bioavailability and PK variability with early start of ART was found in this cohort of severely malnourished children; however, these changes did not influence virological outcomes. The study supports the use of weight-band dosage tables.
Authors: Xavier Argemi; Som Dara; Seng You; Jean F Mattei; Christian Courpotin; Bernard Simon; Yves Hansmann; Daniel Christmann; Nicolas Lefebvre Journal: AIDS Date: 2012-06-01 Impact factor: 4.177
Authors: Louisa Pollock; Laura Else; Goenke Poerksen; Elizabeth Molyneux; Peter Moons; Sarah Walker; William Fraser; David Back; Saye Khoo Journal: J Antimicrob Chemother Date: 2009-10-06 Impact factor: 5.790
Authors: D M Burger; G Verweel; N Rakhmanina; C P W G M Verwey-Van Wissen; C J L La Porte; A S Bergshoeff; H Lyall; N G Hartwig; H Green; S Soldin; D M Gibb; R de Groot Journal: Clin Pharmacol Ther Date: 2007-02-28 Impact factor: 6.875
Authors: Aaloke Mody; Sarah Bartz; Christoph P Hornik; Tonny Kiyimba; James Bain; Michael Muehlbauer; Elizabeth Kiboneka; Robert Stevens; John V St Peter; Christopher B Newgard; John Bartlett; Michael Freemark Journal: PLoS One Date: 2014-07-22 Impact factor: 3.240
Authors: Adrie Bekker; Edmund V Capparelli; Avy Violari; Mark F Cotton; Mae Cababasay; Jiajia Wang; Ruth Mathiba; Lubbe Wiesner; Andrew Wiznia; Pearl Samson; Renee Browning; Jack Moye; Firdose L Nakwa; Eric Decloedt; Helena Rabie; Mark Mirochnick; Tim R Cressey Journal: Lancet HIV Date: 2021-12-06 Impact factor: 16.070
Authors: Tjokosela Tikiso; Helen McIlleron; David Burger; Diana Gibb; Helena Rabie; Janice Lee; Marc Lallemant; Mark F Cotton; Moherndran Archary; Stefanie Hennig; Paolo Denti Journal: Br J Clin Pharmacol Date: 2021-08-12 Impact factor: 3.716
Authors: Luka Verrest; Erica A Wilthagen; Jos H Beijnen; Alwin D R Huitema; Thomas P C Dorlo Journal: Clin Pharmacokinet Date: 2021-06-01 Impact factor: 5.577